Northwest & Ethical Investments’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.8M Sell
27,350
-7,151
-21% -$7.31M 0.76% 28
2026
Q1
$31.7M Buy
34,501
+1,371
+4% +$1.39M 0.73% 34
2025
Q4
$35.6M Buy
33,130
+115
+0.3% +$110K 0.8% 24
2025
Q3
$25.1M Buy
33,015
+4,410
+15% +$3.28M 0.59% 48
2025
Q2
$22.3M Sell
28,605
-1,301
-4% -$1.01M 0.55% 56
2025
Q1
$24.7M Buy
29,906
+2,589
+9% +$2.15M 0.67% 39
2024
Q4
$21.1M Sell
27,317
-7,960
-23% -$6.59M 0.57% 52
2024
Q3
$31.3M Buy
35,277
+7,154
+25% +$6.43M 0.83% 23
2024
Q2
$25.5M Buy
28,123
+5,730
+26% +$4.58M 0.73% 33
2024
Q1
$17.4M Buy
22,393
+411
+2% +$292K 0.5% 64
2023
Q4
$12.8M Sell
21,982
-3,440
-14% -$2.01M 0.39% 84
2023
Q3
$13.7M Sell
25,422
-15,188
-37% -$7.83M 0.46% 73
2023
Q2
$19M Buy
40,610
+11,021
+37% +$4.62M 0.61% 45
2023
Q1
$10.2M Sell
29,589
-6,273
-17% -$2.12M 0.34% 97
2022
Q4
$13.1M Buy
35,862
+6,202
+21% +$2.2M 0.45% 76
2022
Q3
$9.59M Buy
29,660
+625
+2% +$198K 0.38% 84
2022
Q2
$9.41M Sell
29,035
-793
-3% -$238K 0.35% 88
2022
Q1
$8.54M Sell
29,828
-6,996
-19% -$1.8M 0.27% 108
2021
Q4
$10.2M Sell
36,824
-2,379
-6% -$603K 0.3% 101
2021
Q3
$9.06M Sell
39,203
-12,073
-24% -$2.98M 0.3% 105
2021
Q2
$11.8M Sell
51,276
-1,719
-3% -$345K 0.38% 83
2021
Q1
$9.9M Sell
52,995
-4,165
-7% -$815K 0.35% 91
2020
Q4
$9.65M Buy
57,160
+7,673
+16% +$1.15M 0.37% 91
2020
Q3
$7.33M Buy
49,487
+2,514
+5% +$389K 0.32% 103
2020
Q2
$7.71M Sell
46,973
-17,291
-27% -$2.65M 0.37% 92
2020
Q1
$8.91M Sell
64,264
-5,664
-8% -$778K 0.52% 55
2019
Q4
$9.19M Sell
69,928
-5,906
-8% -$685K 0.41% 73
2019
Q3
$8.48M Buy
75,834
+9,784
+15% +$1.09M 0.41% 76
2019
Q2
$7.32M Buy
66,050
+13,216
+25% +$1.56M 0.37% 87
2019
Q1
$6.86M Buy
52,834
+23,238
+79% +$2.83M 0.36% 82
2018
Q4
$3.42M Buy
29,596
+17,536
+145% +$1.96M 0.2% 148
2018
Q3
$1.29M Sell
12,060
-39,280
-77% -$3.93M 0.08% 272
2018
Q2
$4.38M Buy
51,340
+2,900
+6% +$238K 0.29% 106
2018
Q1
$3.75M Buy
48,440
+2,800
+6% +$225K 0.25% 121
2017
Q4
$3.85M Buy
45,640
+16,069
+54% +$1.37M 0.25% 124
2017
Q3
$2.53M Buy
29,571
+1,300
+5% +$107K 0.16% 175
2017
Q2
$2.29M Buy
28,271
+800
+3% +$65.3K 0.16% 170
2017
Q1
$2.31M Sell
27,471
-28,600
-51% -$2.29M 0.16% 170
2016
Q4
$4.12M Sell
56,071
-55,229
-50% -$4.11M 0.28% 87
2016
Q3
$8.93M Sell
111,300
-105,200
-49% -$8.42M 0.63% 32
2016
Q2
$17M Buy
216,500
+166,900
+336% +$12.6M 1.29% 16
2016
Q1
$3.57M Sell
49,600
-2,900
-6% -$219K 0.24% 108
2015
Q4
$4.42M Sell
52,500
-92,050
-64% -$7.64M 0.32% 91
2015
Q3
$12.1M Sell
144,550
-115,800
-44% -$9.78M 0.93% 27
2015
Q2
$21.7M Buy
260,350
+79,150
+44% +$6.03M 1.43% 16
2015
Q1
$13.2M Sell
181,200
-79,000
-30% -$5.62M 0.92% 21
2014
Q4
$18M Sell
260,200
-20,600
-7% -$1.39M 1.21% 17
2014
Q3
$18.2M Buy
280,800
+27,600
+11% +$1.75M 1.22% 15
2014
Q2
$15.7M Buy
+253,200
New +$15.1M 0.98% 22

Other funds holding LLY

Northwest & Ethical Investments's LLY Position: Q2 2026 in Review

Northwest & Ethical Investments reduced its Eli Lilly (LLY) stake by 21% in Q2 2026, selling an estimated $7.31M and leaving 27,350 shares worth $32.8M. The position accounts for 0.76% of the portfolio, ranked #28.

Northwest & Ethical Investments first reported a position in LLY in Q2 2014 and has held it in 49 quarters since. The position peaked at $35.6M in Q4 2025. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Northwest & Ethical Investments held 27,350 shares of Eli Lilly worth $32.8M as of Q2 2026.
  • Northwest & Ethical Investments sold 7,151 Eli Lilly shares in Q2 2026, an estimated $7.31M.
  • Eli Lilly made up 0.76% of Northwest & Ethical Investments's portfolio in Q2 2026, its #28 holding.
  • Northwest & Ethical Investments first reported a position in Eli Lilly in Q2 2014 and has held it in 49 quarters since.
  • Northwest & Ethical Investments's Eli Lilly position peaked at $35.6M in Q4 2025.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Northwest & Ethical Investments's 13F filing for Q2 2026, filed 13 Aug 2026.